title: A highly insoluble state of Abeta similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice.
abstract: Amyloid-beta (Abeta) is a major drug target in Alzheimer's disease. Here, we demonstrate that deposited Abeta is SDS insoluble in tgAPP-ArcSwe, a transgenic mouse model harboring the Arctic (E693G) and Swedish (KM670/671NL) APP mutations. Formic acid was needed to extract the majority of deposited Abeta in both tgAPP-ArcSwe and Alzheimer's disease brain, but not in a commonly used type of mouse model with the Swedish mutation alone. Interestingly, the insoluble state of Arctic Abeta was determined early on and did not gradually evolve with time. In tgAPP-ArcSwe, Abeta plaques displayed a patchy morphology with bundles of Abeta fibrils, whereas amyloid cores in tgAPP-Swe were circular with radiating fibrils. Amyloid was more densely stacked in tgAPP-ArcSwe, as demonstrated with a conformation sensitive probe. A reduced increase in plasma Abeta was observed following acute administration of an Abeta antibody in tgAPP-ArcSwe, results that might imply reduced brain to plasma Abeta efflux. TgAPP-ArcSwe, with its insoluble state of deposited Abeta, could serve as a complementary model to better predict the outcome of clinical trials.
authors.affiliation: Department of Public Health and Caring Science, Uppsala University, Sweden.
authors.forename: Ola
authors.initials: O
authors.lastname: Philipson
authors.forename: Per
authors.initials: P
authors.lastname: Hammarström
authors.forename: K Peter R
authors.initials: KP
authors.lastname: Nilsson
authors.forename: Erik
authors.initials: E
authors.lastname: Portelius
authors.forename: Tommie
authors.initials: T
authors.lastname: Olofsson
authors.forename: Martin
authors.initials: M
authors.lastname: Ingelsson
authors.forename: Bradley T
authors.initials: BT
authors.lastname: Hyman
authors.forename: Kaj
authors.initials: K
authors.lastname: Blennow
authors.forename: Lars
authors.initials: L
authors.lastname: Lannfelt
authors.forename: Hannu
authors.initials: H
authors.lastname: Kalimo
authors.forename: Lars N G
authors.initials: LN
authors.lastname: Nilsson
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000235:genetics* / Q000378:metabolism* / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D016564:Amyloid beta-Protein Precursor / Q000235:genetics*; D000818:Animals; D000906:Antibodies / Q000494:pharmacology / Q000627:therapeutic use; D001921:Brain / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D004195:Disease Models, Animal; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D046529:Microscopy, Electron, Transmission; D009154:Mutation / Q000235:genetics; D058225:Plaque, Amyloid / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D012995:Solubility
chemical_list: D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D000906:Antibodies